Researchers from Peking University discovered a tumor-specific biomarker that can predict which gastric cancer patients will ...
Adding to adjuvant mFOLFOX6 significantly improved outcomes in resected stage III dMMR colon cancer, reducing recurrence or ...
University of Michigan researchers developed serum albumin-based nanoparticles that delivered plasmid DNA and mRNA into ...
A multicentre study found that an AI model using routine H&E pathology slides and clinicopathological data could estimate genomic recurrence risk and predict chemotherapy benefit in hormone ...
BioNTech SE will present the latest clinical updates from its late-stage lung cancer portfolio at ELCC 2026, highlighting ...
The FDA has approved nivolumab (Opdivo) plus AVD as first-line treatment for advanced classical Hodgkin lymphoma in patients ...
TG Therapeutics secured $500 million in non-dilutive capital through a new credit facility, supporting the expansion of ...
Agilent has received FDA approval for PD-L1 IHC 22C3 pharmDx, Code SK006, as a companion diagnostic to identify patients with esophageal or gastroesophageal junction carcinoma eligible for ...
Phase 3 WU-KONG28 trial met its primary endpoint, showing that once-daily oral sunvozertinib significantly improved ...
A Nature study identifies a previously unknown protein modification, O-2-hydroxyglutarylation, driven by the oncometabolite ...
Mayo Clinic has launched the first U.S. clinical research program using magnetic nanoparticle-mediated hyperthermia for ...
Phase 3 TALAPRO-3 results show that talazoparib plus enzalutamide significantly improves radiographic progression-free ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results